Capital Royalty Acquires Interest in One of the Largest Oncology Drugs in the Market

In the first Quarter of 2007, Capital Royalty acquired a royalty entitlement in a novel small molecule oncology treatment from a leading hospital system in the U.S.   

Capital Royalty worked closely with the royalty holder and its advisors to structure a transaction that provided in excess of $100 million in exchange for an interest in the royalty stream of the oncology drug’s revenues. Capital Royalty worked with a co-investor to facilitate funding the entire transaction at close. 

By patiently working with the royalty holder’s board as they evaluated the transaction and being quick to respond to the holder’s request to review multiple unique structures, Capital Royalty was awarded the transaction over a competitor.  Today, the drug is being studied in more than 50 clinical trials and entering new markets, both of which are contributing to a rapid rise in global revenue for the product.